Gastrointestinal Cancer

The addition of durvalumab to standard neoadjuvant chemotherapy significantly improved pathologic complete response over neoadjuvant chemotherapy alone in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.

When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.

Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma.

Patients with unresectable hepatocellular carcinoma experienced manageable and low-grade immune-related adverse events with single tremelimumab regular interval durvalumab.

Michael K. Gibson MD, PhD, discusses the importance of addressing unmet needs related to treatment for patients with gastrointestinal cancers.

The China National Medical Products Adminstration’s Center for Drug Evaluation has recommended that olverembatinib receive breakthrough therapy designation for the treatment of patients with gastrointestinal stromal tumor that is succinate dehydrogenase deficient.

STAT2 expression in patients with hepatocellular carcinoma increases with tumor grade and cancer stage, with increases occurring at greater rates among Asian and African American patients.

Individuals in Philadelphia and New York City who were screened for the common liver cancer risk factors hepatitis B virus or hepatitis C virus displayed a higher level of knowledge of liver cancer.

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

Minimally invasive distal pancreatectomy was found to be a safe and effective alternative to that of open distal pancreatectomy in patients with resectable pancreatic cancer, confirmed by a noninferior radical resection rate, lymph node yield, and comparable survival data.

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.

CLDN18.2 has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer, gastroesophageal junction cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

The FDA has granted an orphan drug designation to mitazalimab for use as a potential therapeutic option in patients with pancreatic cancer.

The combination of GEN-002 and avelumab elicited responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from an interim analysis of an ongoing phase 2 trial.

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

The FDA has granted an orphan drug designation to rucosopasem manganese for the treatment of patients with pancreatic cancer.

A new drug application has been submitted to the FDA for the combination of rivoceranib and camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.

Adjuvant treatment with the individualized RNA neoantigen vaccine autogene cevumeran in combination with atezolizumab and chemotherapy induced notable T-cell activity that could be correlated with delayed recurrence in patients with pancreatic ductal adenocarcinoma.

The FDA has granted an orphan drug designation to PYX-201 for the treatment of patients with pancreatic cancer.

Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.